tiprankstipranks
Advertisement
Advertisement

PVLA Stock Latest News

Short Report: Bears book profits in Celcuity
The FlyShort Report: Bears book profits in Celcuity
7d ago
ARRY
BOBS
What the $10B Crinetics Deal & $2.9B Soleno Acquisition Might Say About Palatin’s Rare-Obesity Opportunity
PremiumTipRanks Newswire
What the $10B Crinetics Deal & $2.9B Soleno Acquisition Might Say About Palatin’s Rare-Obesity Opportunity
11d ago
PTN
CRNX
Analyst Reiterates Buy on Palvella, Sees Market Overreaction to CVM Setback and Maintains $227 Price Target
PremiumRatings
Analyst Reiterates Buy on Palvella, Sees Market Overreaction to CVM Setback and Maintains $227 Price Target
12d ago
PVLA
Palvella Pharmaceuticals: Buy Rating Reiterated as QTORIN Regulatory Path Stays Intact; Price Target Unchanged at $225
PremiumRatings
Palvella Pharmaceuticals: Buy Rating Reiterated as QTORIN Regulatory Path Stays Intact; Price Target Unchanged at $225
12d ago
PVLA
H.C. Wainwright says Palvella selloff ‘an overreaction’ to FDA’s BTD denial
PremiumThe Fly
H.C. Wainwright says Palvella selloff ‘an overreaction’ to FDA’s BTD denial
12d ago
PVLA
Palvella Therapeutics selloff a buying opportunity, says BTIG
PremiumThe FlyPalvella Therapeutics selloff a buying opportunity, says BTIG
12d ago
PVLA
Palvella Therapeutics falls -13.6%
Premium
The Fly
Palvella Therapeutics falls -13.6%
13d ago
PVLA
Palvella Therapeutics falls -9.0%
Premium
The Fly
Palvella Therapeutics falls -9.0%
13d ago
PVLA
Ligand price target raised to $345 from $330 at Craig-Hallum
PremiumThe Fly
Ligand price target raised to $345 from $330 at Craig-Hallum
13d ago
SNY
LGND
Palvella Therapeutics Highlights Growth Plans and QTORIN Progress
PremiumCompany Announcements
Palvella Therapeutics Highlights Growth Plans and QTORIN Progress
19d ago
8K
PVLA
Palvella Therapeutics Adds Industry Veteran to Board
PremiumCompany Announcements
Palvella Therapeutics Adds Industry Veteran to Board
1M ago
8K
PVLA
Palvella Therapeutics appoints Savara CEO Matt Pauls to board
PremiumThe Fly
Palvella Therapeutics appoints Savara CEO Matt Pauls to board
1M ago
PVLA
SVRA
Palvella submits first rolling new drug application to FDA for Qtorin
PremiumThe FlyPalvella submits first rolling new drug application to FDA for Qtorin
1M ago
PVLA
FDA grants rolling review to Palvella Therapeutics Qtorin rapamycin
Premium
The Fly
FDA grants rolling review to Palvella Therapeutics Qtorin rapamycin
1M ago
PVLA
Palvella Therapeutics Expands Equity Plan, Confirms Board Leadership
Premium
Company Announcements
Palvella Therapeutics Expands Equity Plan, Confirms Board Leadership
2M ago
8K
PVLA
Palvella Therapeutics completes Qtorin pre-new drug application meeting with FDA
PremiumThe Fly
Palvella Therapeutics completes Qtorin pre-new drug application meeting with FDA
2M ago
PVLA
Palvella Therapeutics issued patent by USPTO for Qtorin pitavastatin program
PremiumThe Fly
Palvella Therapeutics issued patent by USPTO for Qtorin pitavastatin program
2M ago
PVLA
Buy Rating Reiterated on Palvella as QTORIN Data Strengthen and $227 Price Target Remains Unchanged
PremiumRatings
Buy Rating Reiterated on Palvella as QTORIN Data Strengthen and $227 Price Target Remains Unchanged
2M ago
PVLA
Fein Reiterates Buy on PVLA, Maintains $270 Price Target on Strong QTORIN Rapamycin Data and Clear Regulatory Path
PremiumRatings
Fein Reiterates Buy on PVLA, Maintains $270 Price Target on Strong QTORIN Rapamycin Data and Clear Regulatory Path
2M ago
PVLA
Palvella Reports Positive Phase 3 Data for QTORIN
PremiumCompany AnnouncementsPalvella Reports Positive Phase 3 Data for QTORIN
2M ago
8K
PVLA
Palvella Therapeutics announces new data from SELVA, TOIVA studies
Premium
The Fly
Palvella Therapeutics announces new data from SELVA, TOIVA studies
2M ago
PVLA
Palvella Unveils Promising Phase 2 Data for QTORIN
Premium
Company Announcements
Palvella Unveils Promising Phase 2 Data for QTORIN
3M ago
8K
PVLA

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >